Health and Me on MSN1d
If You’ve Never Smoked, Why Are You At Risk For Lung Cancer?Dust, smoke, and chemicals in the air cause about 1%-2% of lung cancers. Researchers suspect that polluted air can cause ...
Sichuan Kelun-Biotech Biopharma has become the first drugmaker to usher a TROP2-targeted antibody-drug conjugate to ...
Fintel reports that on March 11, 2025, HC Wainwright & Co. downgraded their outlook for Checkpoint Therapeutics ...
DelveInsight's "TAGRISSO Market Size, Forecast, and Market Insight Report" highlights the details around TAGRISSO, a kinase ...
During a live event, Alexander I. Spira, MD, PhD, and participants discuss efficacy, adverse events, and sequencing of EGFR-mutated NSCLC treatments.
Checkpoint Therapeutics gains approval for cosibelimab but faces financial challenges and tough competition. Learn more about ...
Biotech’s TROP2 antibody drug conjugate sac-TMT for marketing in second indication: Chengdu, China Wednesday, March 12, 2025, 11:00 Hrs [IST] Sichuan K ...
News Medical on MSN10d
Co-Occurring Mutations Drive Therapy Resistance in KRAS G12C CancersColorectal cancer and pancreatic ductal adenocarcinoma that harbored the KRAS G12C mutation often carried other genetic ...
This has been a productive year for ArriVent that included strong achievement across our firmonertinib clinical programs and significant ...
First clinical data demonstrating robust confirmed responses and CNS anti-tumor activity for firmonertinib in first-line NSCLC EGFR PACC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback